Project title: Ex vivo compound prioritization for gastroenteropancreatic NETs
Andrea Califano, PhD Columbia University
- Status: Completed
- Year(s): 2015
- Research Type: Translational
- Primary Tumor Site: Small intestine
- Area of Inquiry: Signaling/drug targets
This project follows the Columbia team’s identification of master regulator genes driving progression of gastroenteropancreatic neuroendocrine tumor to metastatic disease and of specific FDA approved drugs and investigational compounds that inhibit the activity of their associated proteins. These include compounds whose ability to abrogate master regulator has been validated in human tumors transplanted into immunocompromised mice. The new study aims to test the most specific and promising among these compounds to validate their ability to abrogate the aberrant activity of the identified master regulator proteins in tissue explants directly harvested from patients, which more closely represent the biology of the human tumor.
- State: New York
- Grant Duration: 2 years
- Awards: No information
NETRF funds laboratory research to understand the development of neuroendocrine tumors and translational research to explore new concepts in treatment. Research grant descriptions and research updates from NETRF are not intended to serve as medical advice. It can take years for research discoveries to be fully validated and approved for patient care. Always consult your health care providers about your treatment options.